Literature DB >> 11705254

Cutaneous drug reaction case reports: from the world literature.

.   

Abstract

Skin disorders are the most common adverse reactions attributed to drugs. Any skin disorder can be imitated, induced or aggravated by drugs. To help you keep up-to-date with the very latest skin reactions occurring with both new and established drugs, this section of the journal brings you information selected from the adverse drug reaction alerting service Reactions Weekly. The following case reports are selected from the very latest to be published in the world dermatology literature. Any claim of a first report has been verified by a search of AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and Medline. Each case report is assessed for seriousness using the FDA MedWatch definition of serious (patient outcome is: death; life-threatening; hospitalization; disability; congenital anomaly; or requires intervention to prevent permanent impairment or damage).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705254     DOI: 10.2165/00128071-200102040-00008

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  3 in total

1.  Acneiform Rash Caused by an Unlikely Drug: Topiramate.

Authors:  Yesenia Bello-Hernández; Jessica Espinoza-Hernández; Gabriela Moreno-Coutiño
Journal:  Skin Appendage Disord       Date:  2017-07-06

Review 2.  Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.

Authors:  Kalliopi Gerogianni; Aspasia Tsezou; Konstantinos Dimas
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.476

Review 3.  Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Pablo Luis Lopez; Fernando Manuel Torrente; Agustín Ciapponi; Alicia Graciela Lischinsky; Marcelo Cetkovich-Bakmas; Juan Ignacio Rojas; Marina Romano; Facundo F Manes
Journal:  Cochrane Database Syst Rev       Date:  2018-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.